228 related articles for article (PubMed ID: 35017665)
1. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.
He DD; Shang XY; Wang N; Wang GX; He KY; Wang L; Han ZG
Oncogene; 2022 Mar; 41(10):1397-1409. PubMed ID: 35017665
[TBL] [Abstract][Full Text] [Related]
2. ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.
Oba A; Shimada S; Akiyama Y; Nishikawaji T; Mogushi K; Ito H; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Asahara H; Kaida A; Miura M; Tanabe M; Tanaka S
J Hepatol; 2017 May; 66(5):942-951. PubMed ID: 28238438
[TBL] [Abstract][Full Text] [Related]
3. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.
Jiang H; Cao HJ; Ma N; Bao WD; Wang JJ; Chen TW; Zhang EB; Yuan YM; Ni QZ; Zhang FK; Ding XF; Zheng QW; Wang YK; Zhu M; Wang X; Feng J; Zhang XL; Cheng SQ; Ma DJ; Qiu L; Li JJ; Xie D
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4770-4780. PubMed ID: 32071245
[TBL] [Abstract][Full Text] [Related]
4. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone I suppresses hepatocellular carcinoma cells growth through targeting DNA double-strand break repair.
Qian Z; Feng N; Geng A
Cancer Biol Ther; 2023 Dec; 24(1):2229958. PubMed ID: 37408176
[TBL] [Abstract][Full Text] [Related]
6. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?
Pascale RM; Joseph C; Latte G; Evert M; Feo F; Calvisi DF
DNA Repair (Amst); 2016 Nov; 47():12-20. PubMed ID: 27789167
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
8. BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.
Li X; Baek G; Ramanand SG; Sharp A; Gao Y; Yuan W; Welti J; Rodrigues DN; Dolling D; Figueiredo I; Sumanasuriya S; Crespo M; Aslam A; Li R; Yin Y; Mukherjee B; Kanchwala M; Hughes AM; Halsey WS; Chiang CM; Xing C; Raj GV; Burma S; de Bono J; Mani RS
Cell Rep; 2018 Jan; 22(3):796-808. PubMed ID: 29346775
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
[TBL] [Abstract][Full Text] [Related]
10. Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression.
Duan Y; Tian L; Gao Q; Liang L; Zhang W; Yang Y; Zheng Y; Pan E; Li S; Tang N
Oncotarget; 2016 Jul; 7(29):45863-45875. PubMed ID: 27351279
[TBL] [Abstract][Full Text] [Related]
11. The SWI/SNF ATPase BRG1 stimulates DNA end resection and homologous recombination by reducing nucleosome density at DNA double strand breaks and by promoting the recruitment of the CtIP nuclease.
Hays E; Nettleton E; Carter C; Morales M; Vo L; Passo M; Vélez-Cruz R
Cell Cycle; 2020 Nov; 19(22):3096-3114. PubMed ID: 33044911
[TBL] [Abstract][Full Text] [Related]
12. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
13. BRG1 promotes the repair of DNA double-strand breaks by facilitating the replacement of RPA with RAD51.
Qi W; Wang R; Chen H; Wang X; Xiao T; Boldogh I; Ba X; Han L; Zeng X
J Cell Sci; 2015 Jan; 128(2):317-30. PubMed ID: 25395584
[TBL] [Abstract][Full Text] [Related]
14. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
Wang C; Tang H; Geng A; Dai B; Zhang H; Sun X; Chen Y; Qiao Z; Zhu H; Yang J; Chen J; He Q; Qin N; Xie J; Tan R; Wan X; Gao S; Jiang Y; Sun FL; Mao Z
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26356-26365. PubMed ID: 33020270
[TBL] [Abstract][Full Text] [Related]
15. TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.
Geng L; Zhu M; Luo D; Chen H; Li B; Lao Y; An H; Wu Y; Li Y; Xia A; Shi Y; Tong Z; Lu S; Xu D; Wang X; Zhang W; Sun B; Xu Z
Oncogene; 2024 Feb; 43(9):682-692. PubMed ID: 38216672
[TBL] [Abstract][Full Text] [Related]
16. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
17. The bromodomain inhibitor JQ1 up-regulates the long non-coding RNA MALAT1 in cultured human hepatic carcinoma cells.
Choi HI; An GY; Yoo E; Baek M; Binas B; Chai JC; Lee YS; Jung KH; Chai YG
Sci Rep; 2022 May; 12(1):7779. PubMed ID: 35546353
[TBL] [Abstract][Full Text] [Related]
18. NELF complex fosters BRCA1 and RAD51 recruitment to DNA damage sites and modulates sensitivity to PARP inhibition.
Bishara LA; Machour FE; Awwad SW; Ayoub N
DNA Repair (Amst); 2021 Jan; 97():103025. PubMed ID: 33248388
[TBL] [Abstract][Full Text] [Related]
19. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
20. The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes.
de Castro RO; Previato L; Goitea V; Felberg A; Guiraldelli MF; Filiberti A; Pezza RJ
J Biol Chem; 2017 May; 292(20):8459-8471. PubMed ID: 28381560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
